A comprehensive review of Valium prescriptions is set to be conducted for hundreds of individuals in England due to apprehensions over extended usage of the drug.
Change Grow Live (CGL), operating in Cambridgeshire, came under scrutiny by the Local Government & Social Care Ombudsman for its benzodiazepine prescriptions, primarily involving diazepam (marketed as Valium).
The ombudsman recommended that CGL investigate the cases of 343 additional clients who are on similar long-term prescriptions.
Acknowledging the inquiry, the ombudsman’s office mentioned that the charity had exhibited full cooperation.
Benzodiazepines belong to a class of medications that include diazepam (Valium) and are prescribed to alleviate anxiety-related symptoms such as nervousness and tension.
However, the National Health Service (NHS) advises against their use for more than four weeks. According to the ombudsman, prolonged prescriptions can lead to increased dependence, withdrawal symptoms, and the development of drug-seeking behavior.
Nigel Ellis, Chief Executive of the Ombudsman, emphasized the significance of clinicians carefully weighing the advantages and risks for patients receiving these medicines on a long-term basis, with a clear rationale for continued prescription.
The examination of CGL followed a complaint against the service, which was operating on behalf of Cambridgeshire County Council.
A clinician from the charity noted in September 2022 that three out of nine clients lacked a “recorded rationale for the prescription,” deviating from the guidance provided by NHS England.
